Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Portland, OR
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Charleston, SC
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Norfolk, VA
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated:  3/25/2013
Clinical Research Facility
mi
from
Seattle, WA
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Status: Enrolling
Updated: 3/25/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated:  3/26/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated: 3/26/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated:  3/26/2013
Cancer Center of Kansas
mi
from
Wichita, KA
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated: 3/26/2013
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated:  3/26/2013
Peggy and Charles Stephenson Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Status: Enrolling
Updated: 3/26/2013
Peggy and Charles Stephenson Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Encino, CA
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Tampa, FL
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Memphis, TN
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
San Diego VA Hospital
mi
from
San Diego, CA
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
San Diego VA Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Michigan Health System
mi
from
Ann Arbor, MI
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Mississippi
mi
from
Jackson, MS
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Mississippi
mi
from
Jackson, MS
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Missouri-Ellis Fischel Cancer Center
mi
from
Columbia, MO
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Missouri-Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
University of Nebraska
mi
from
Omaha, NE
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
Thomas Jefferson University
mi
from
Philadelphia, PA
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/28/2013
MD Anderson
mi
from
Houston, TX
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/28/2013
MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
TGEN Clinical Research Service at Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
TGEN Clinical Research Service at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
Texas Oncology-Tyler
mi
from
Tyler, TX
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated:  3/28/2013
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Status: Enrolling
Updated: 3/28/2013
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7
Status: Enrolling
Updated:  3/29/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7
Status: Enrolling
Updated: 3/29/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.
Status: Enrolling
Updated:  4/1/2013
National Cancer Institute, NIH, US
mi
from
Bethesda, MD
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.
Status: Enrolling
Updated: 4/1/2013
National Cancer Institute, NIH, US
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer
Status: Enrolling
Updated:  4/4/2013
Rhode Island Hospital
mi
from
Providence, RI
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer
Status: Enrolling
Updated: 4/4/2013
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer
Status: Enrolling
Updated:  4/4/2013
Miriam Hospital
mi
from
Providence, RI
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer
Status: Enrolling
Updated: 4/4/2013
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Community Regional Medical Center
mi
from
Fresno, CA
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Community Regional Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Penrose Cancer Center
mi
from
Colorado Springs, CO
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Penrose Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Jupiter Medical Center
mi
from
Jupiter, FL
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Jupiter Medical Center
mi
from
Jupiter, FL
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Parkview Cancer Center
mi
from
Fort Wayne, IN
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Parkview Cancer Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Central Baptist Hospital
mi
from
Lexington, KY
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Central Baptist Hospital
mi
from
Lexington, KY
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
St. Mary's of Michigan
mi
from
Saginaw, MI
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
St. Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
St. Mary's
mi
from
Reno, NV
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
St. Mary's
mi
from
Reno, NV
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Denver CyberKnife
mi
from
Lone Tree, CO
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Denver CyberKnife
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Saint Louis University
mi
from
Saint Louis, MO
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
UT MD Anderson Cancer Center
mi
from
Houston, TX
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials